Stocks Health care WST
NYSE · Health careWest Pharmaceutical Services Inc (WST)
West Pharmaceutical Services Inc brought in $3.3B of revenue over the twelve months to June 30, 2026, up 12.4% from a year earlier. Net income was $564.9M, a net margin of 17.0%. Operating cash flow minus capital spending left $468.9M of free cash flow in fiscal 2025. At June 30, 2026 it held $435.8M in cash against $202.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 23, 2026.
Key facts about West Pharmaceutical Services Inc
- Net worth
- West Pharmaceutical Services Inc has a market value (market cap) of $25.9B at the latest share price, and shareholders' equity of $3B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3.1B (+6.3% year on year), with net income of $493.7M. Over the 12 months to June 30, 2026: revenue $3.3B, net income $564.9M.
- Cash flow
- In fiscal 2025 operations brought in $754.8M of cash; after $285.9M of capital spending, free cash flow was $468.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 23, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- West Pharmaceutical Services Inc's next report is expected around October 22, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- West Pharmaceutical Services Inc declared dividends of $0.86 per share in fiscal 2025, a yield of 0.23% at the current price.
What West Pharmaceutical Services Inc does
West Pharmaceutical Services designs and manufactures packaging and delivery components for injectable drugs. Its products include rubber stoppers, syringe components, vial seals, and auto-injectors sold to pharmaceutical and biotechnology companies. Its shares trade on NYSE under the ticker WST.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.1B | $493.7M | $6.79 | $468.9M |
| 2024 | $2.9B | $492.7M | $6.69 | $276.4M |
| 2023 | $2.9B | $593.4M | $7.88 | $414.5M |
| 2022 | $2.9B | $585.9M | $7.73 | $439.4M |
| 2021 | $2.8B | $661.8M | $8.67 | $330.6M |
| 2020 | $2.1B | $346.2M | $4.57 | $298.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where WST ranks in Health care
Dividends
West Pharmaceutical Services Inc declared $0.86 per share in fiscal 2025. At the current price that is a yield of 0.23%. It paid out $61.2M in cash dividends, 12% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $0.86 | $61.2M | 12% |
| 2024 | $0.82 | $59.1M | 12% |
| 2023 | $0.78 | $57M | 10% |
| 2022 | $0.74 | $54.1M | 9% |
| 2021 | $0.70 | $51.1M | 8% |
| 2020 | $0.66 | $48.1M | 14% |
Latest SEC filings
What West Pharmaceutical Services Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- July 23, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 14% to $872.3M versus the same quarter last year; diluted EPS $2.15 versus $1.82.
- July 23, 2026
- July 14, 2026
- June 1, 2026
- May 20, 2026Cybersecurity incident 8-K/A
- May 13, 2026
- May 11, 2026
- May 5, 2026
- April 30, 2026Passive stake (5% or more) SCHEDULE 13G
What is WST worth? A DCF from its reported cash flow
Insider trades
What the people running West Pharmaceutical Services Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $5.4M worth of shares in the last 90 days and bought none on the open market. 49% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 15, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Exercised options | 2,524 | $226.3K |
| September 15, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Soldpre-planned (10b5-1) | 2,524 | $921.3K |
| September 14, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Exercised options | 2,500 | $224.1K |
| September 14, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Soldpre-planned (10b5-1) | 2,500 | $887.5K |
| September 11, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Exercised options | 2,500 | $224.1K |
| September 11, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Soldpre-planned (10b5-1) | 2,500 | $862.5K |
| September 8, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Exercised options | 2,817 | $235.1K |
| September 8, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Sold | 2,817 | $960.1K |
Who owns WST
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.48% | April 30, 2026 |
| Vanguard Portfolio Management13G, passive | 5.69% | April 29, 2026 |
| Fmr LLC13G, passive with 1 related filers | 5% | August 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 830 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 6,651,784 | -184,930 |
| Vanguard Capital Management LLC | 4,613,134 | -70,152 |
| Vanguard Portfolio Management LLC | 4,015,766 | -78,243 |
| Fmr LLC | 3,574,816 | +2,325,068 |
| State Street Corp | 3,348,698 | +54,920 |
| Artisan Partners Limited Partnership | 2,411,792 | -246,101 |
| Bank of New York Mellon Corp | 2,043,823 | -422,035 |
| Generation Investment Management Llp | 2,028,322 | -215,654 |
| Geode Capital Management, LLC | 1,903,279 | -9,176 |
| Morgan Stanley | 1,582,546 | +124,264 |
| Jpmorgan Chase & Co | 1,164,527 | +121,110 |
| Brown Advisory Inc | 1,075,309 | -265,568 |
| Longview Partners (Guernsey) LTD | 1,033,826 | -281,577 |
| Invesco Ltd. | 1,009,852 | -46,155 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 884,865 | -17,899 |
| Norges Bank | 862,915 | new |
| Goldman Sachs Group Inc | 814,772 | +87,155 |
| Kayne Anderson Rudnick Investment Management LLC | 760,622 | -97,676 |
| TD Asset Management Inc | 731,054 | -37,899 |
| Northern Trust Corp | 709,421 | -21,862 |
Insiders
17 insiders reported holding 391,084 shares in total, about $144.1M at the last price.
| Holder | Shares |
|---|---|
| Green Eric MarkPresident, CEO and Board Chair, Director | 175,161 |
| Michels Douglas ADirector | 46,496 |
| Buthman Mark ADirector | 44,309 |
| Feehery William FDirector | 32,519 |
| Favorite Annette FSr. VP & Chief HR Officer | 21,818 |
| Lai Goldman MylaDirector | 20,435 |
| Pucci PaoloDirector | 11,854 |
| Keller Deborah LDirector | 11,560 |
| McMahon Robert W.SVP & Chief Financial Officer | 7,021 |
| Friel Robert FDirector | 5,513 |
Questions about WST
What does West Pharmaceutical Services Inc do?
West Pharmaceutical Services designs and manufactures packaging and delivery components for injectable drugs. Its products include rubber stoppers, syringe components, vial seals, and auto-injectors sold to pharmaceutical and biotechnology companies. Its shares trade on NYSE under the ticker WST.
What is West Pharmaceutical Services Inc's net worth?
West Pharmaceutical Services Inc has a market value (market cap) of $25.9B at the latest share price, and shareholders' equity of $3B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is West Pharmaceutical Services Inc profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $564.9M on revenue of $3.3B, a net margin of 17.0%.
How much revenue does West Pharmaceutical Services Inc make?
Over the twelve months to June 30, 2026 West Pharmaceutical Services Inc reported revenue of $3.3B. That is 12.4% more than a year earlier.
When did West Pharmaceutical Services Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 23, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.
When is West Pharmaceutical Services Inc's next earnings report?
West Pharmaceutical Services Inc's next report is expected around October 22, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does West Pharmaceutical Services Inc pay a dividend?
Yes. West Pharmaceutical Services Inc declared dividends of $0.86 per share in fiscal 2025, a yield of 0.23% at the current price.
Theses that mention WST
- The real bottleneck in the GLP-1 boom is not the molecules, it is glass, stoppers and injector pens Live
Similar companies
Compare WST with
Follow WST
Get an email when West Pharmaceutical Services Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values West Pharmaceutical Services Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.